title: Successful treatment with crizotinib in mechanically ventilated patients with ALK positive non-small-cell lung cancer.
abstract: Lung cancer is the most common solid tumor in critically ill cancer patients admitted to intensive care units and is associated with a poor prognosis. Crizotinib is an anaplastic lymphoma kinase (ALK) inhibitor, which is active for advanced non-small cell lung cancer (NSCLC) patients harboring ALK rearrangements. We report three cases of NSCLC patients who required mechanical ventilation for respiratory failure and were successfully weaned from mechanical ventilation after treatment with ALK inhibitors. These responses were accompanied by minimal toxicities and an overt improvement in performance status. These results suggest that ALK inhibitors may be safe and effective in critically ill patients on mechanical ventilation for respiratory failure resulting from EML4-ALK translocated NSCLC progression.
authors: Divisions of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors: Hee Kyung
authors: HK
authors: Ahn
authors: Kyeongman
authors: K
authors: Jeon
authors: Hongseok
authors: H
authors: Yoo
authors: Boram
authors: B
authors: Han
authors: Su Jin
authors: SJ
authors: Lee
authors: Hyeyon
authors: H
authors: Park
authors: Min Ji
authors: MJ
authors: Lee
authors: Sang Yun
authors: SY
authors: Ha
authors: Joung Ho
authors: JH
authors: Han
authors: Jong-Mu
authors: JM
authors: Sun
authors: Jin Seok
authors: JS
authors: Ahn
authors: Myung-Ju
authors: MJ
authors: Ahn
authors: Keunchil
authors: K
authors: Park
mesh_terms: D000230:Adenocarcinoma / Q000150:complications* / Q000628:therapy; D000328:Adult; D000077548:Anaplastic Lymphoma Kinase; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications* / Q000628:therapy; D000077547:Crizotinib; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008175:Lung Neoplasms / Q000150:complications* / Q000628:therapy; D008875:Middle Aged; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D012121:Respiration, Artificial; D012131:Respiratory Insufficiency / Q000188:drug therapy* / Q000209:etiology; D015300:Ventilator Weaning
chemical_list: D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases